PAI1 antibody

Catalog No. ABIN7670718

The Rat Monoclonal anti-PAI1 antibody has been validated for ELISA (Capture). It is suitable to detect PAI1 in samples from Human.

Quick Overview for PAI1 antibody (ABIN7670718)

Target: PAI1 (SERPINE1) (Plasminogen Activator Inhibitor 1 (SERPINE1))

Reactivity: Human

Host: Rat

Clonality: Monoclonal

Conjugate: This PAI1 antibody is un-conjugated

Application: ELISA (Capture)

Clone: 10F2

Product Details anti-PAI1 Antibody

Purpose: Serpin E1/PAI-1 Monoclonal Antibody(Capture)

Purification: Protein A/G Purification

Immunogen: Recombinant Human Serpin E1/PAI-1 Protein expressed by Mammalian

Isotype: IgG2a

Application Details

Application Notes: ELISA Capture 2-8 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Sterile PBS , pH 7.4

Preservative: Without preservative

Handling Advice: Avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C Valid for 1 month or -20°C Valid for 12 months

Expiry Date: 12 months

Target Details for PAI1

Target: PAI1 (SERPINE1) (Plasminogen Activator Inhibitor 1 (SERPINE1))

Alternative Name: Serpin E1/PAI-1

Background: PLasminogen activator inhibitor 1,PAI-1,EndotheLiaL pLasminogen activator inhibitor,Serpin E1,SERPINE1,PLANH1,Plasminogen activator inhibitor 1,also known as PAI-1,Endothelial plasminogen activator inhibitor,SerpinE1 and PlANH1,is a secreted glycoprotein that belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. High concentrations of SerpinE1 have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins,which is based on a metastable native state becoming stabilised by insertion of the RCl into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. PAI-1,in its active state,also binds to the extracellular protein vitronectin. When in complex with its target proteases,it binds with high affinity to endocytosis receptors of the low density receptor family. The mechanisms of PAI-1 overexpression during obesity are complex,and it is conceivable that several inducers are involved at the same time at several sites of synthesis. PAI-1 is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis.

UniProt: P05121

Pathways: p53 Signaling, Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagy, Smooth Muscle Cell Migration